Business · 20/08/2014
FDA Clears Leuprolide Depot Suspension for Abbreviated New Drug Applications
The FDA has determined that two versions of Leuprolide Depot Suspension, a medication used to treat hormone-related cancers, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for abbreviated new drug applications for these formulations.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →